Abstract: RNA interference (RNAi) has potential advantages over other gene therapy approaches due to its high specificity and the ability to inhibit target gene expression. Thus, developing a stable, safe, effective siRNA delivery system is necessary to achieve targeted therapy. Here, we developed such a system by conjugating gelatin-based nanoparticles with the nucleolin-targeted AS1411 aptamer and siRNA sequence together (Apt-GS/siRNA NPs) via a disulphide linker. These Apt-GS/siRNA NPs demonstrated favourable release of siRNA under reducing conditions owing to disulphide cleavage. Furthermore, the Apt-GS/siRNA NPs could selectively deliver siRNA to A549 cells overexpressing nucleolin via a nucleolin-mediated transmembrane process, subsequently resulting in efficient RNAi. These results indicated that the Apt-GS/siRNA NPs could facilitate nucleolin-targeted siRNA delivery and gene silencing in tumours.
Introduction
RNA interference (RNAi) is a promising treatment approach for a wide range of diseases, such as genetic disorders, cancers, and infectious diseases, owing to its high specificity and potency in targeted gene silencing [1, 2] . However, the impermeability of siRNA across the cell membrane and short plasma half-life in vivo (<10 min) necessitate that the delivery vehicle for siRNA must reach the cytoplasm. Nanoparticle-based delivery has potential advantages in effective siRNA stabilization and further modification for site-specific delivery [3] . Gelatin has been employed for siRNA encapsulation due to its excellent biocompatibility, biodegradability, and gelation properties [4] . However, physical entrapment of siRNA has major drawbacks, including low siRNA delivery efficiency, the risk of premature release due to the weak electrostatic interactions between gelatin and siRNAs, and poor endosomal escape. Conjugation of siRNA to a carrier through labile or nonlabile bonds is a promising method for overcoming this delivery challenge. Additionally, poly(lactic-coglycolic acid) (PLGA)/siRNA conjugates formed via a disulphide bond exhibit enhanced encapsulation and delivery efficiency [5] . Productive site-directed delivery of siRNA can enhance transfection and reduce off-target effects, which are required by most practical applications.
Aptamer AS1411 (also known as AGRO100), which can strongly bind to cell surface nucleolin uniquely expressed on tumour cells, has reach phase I and phase II clinical trials as the first nucleic acid aptamer drug for the treatment of cancer in humans [6, 7] . Recently, our group has explored a series of siloxane-crosslinked gelatin nanoparticles (GS NPs) with controlled size and surface charges, demonstrating the transfection efficiency of GS NPs in vitro and in vivo [8, 9] . However, the capacity for efficient drug delivery by combining the aptamer AS1411 and GS NPs has not yet been investigated.
Here, we aimed to investigate whether AS1411 functional GS NPs, generated by conjugating nucleolin-targeted aptamer AS1411 and siRNA to the surface of GS NPs via a cleavable disulphide linker, could improve effective cellular internalization and achieve site-targeted gene silencing of a model gene.
Materials and Methods
Amino-functionalized gelatin/silica nanoparticles (GS NPs) were first prepared by a sol-gel procedure, as previously described [10] . A heterobifunctional crosslinker, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), was used to activate the terminal amino groups of GS at a ratio of more than 1000:1 and was then reacted for 1 h with stirring. For the preparation of aptamerconjugated nanoparticles (Apt-GS NPs), the sulphhydryl-containing DNA aptamer AS1411 was attached to this linker via a maleimide-thiol coupling reaction at room temperature for 12 h. For conjugation of siRNA to Apt-GS, the 5′ thiol siRNA sense strand was reacted with the previously activated Apt-GS NPs (80 mL of a 5 mg/mL solution) via the SPDP crosslinker overnight at 4°C. After washing, the sample was incubated with anti-sense strands for 4 min at 94°C and annealed for 20 min at 47°C to form double-stranded siRNA for luciferase gene silencing (Luc-siRNA). The sequences used in this study were as follows: AS1411, 5′-GGTGGTGGTGGTTGTGGTGGTGGTGGTTTTTTTTTTTT-3′; TDO, 5′-CACCGGGAGGATAGTTCGGTGGCTGTTTTTTTTTTTTT-3′; thiol sense strand of the Luc-siRNA, 5′-SH-(CH2)6-CUUACGCUGAGUACUUCGATT-3′ and anti-sense strand, 5′-TTGAAUGCGACUCAUGAAGCU-3′.
To study the targeting of Apt-GS, A549 human breast adenocarcinoma cells and 3T3 fibroblasts were seeded at 1.5 × 10 5 cells/well in 12-well plates and cultured overnight in RPMI-1640 medium or Dulbecco's modified Eagle's medium (DMEM), respectively, containing 10% foetal bovine serum at 37°C in an atmosphere containing 5% CO2. For confocal laser scanning microscopy observations, the cells were cocultured with 25 μL of Apt-GS and TDO-GS NPs (2 mg/mL) for 10 h in serum-free medium. After washing three times with phosphate-buffered saline (PBS), cells were fixed with paraformaldehyde (4% in PBS) for 30 min and then observed with an inverted SP2-MP2 confocal laser scanning microscope (Leica, Germany). To analyse the dynamics of endocytosis, the cells were incubated with the same amounts of Apt-GS and TDO-GS NPs for different times. The cells were then resuspended in ice-cold PBS, and fluorescent cells were measured using an EPICS XL flow cytometer (Beckman Coulter, USA).
To evaluate the gene knockdown efficiency of siRNA, luciferase-expressing A549 and 3T3 cells were treated with NPs alone for 8 h, NPs for 8 h followed by liposomes for an additional 2 h, or a mixture of NPs and liposomes. After an additional 40 h of incubation, gene knockdown efficiency was investigated by quantifying the luciferase expression in cells using a Luciferase Assay System according to the manufacturer's protocol. Experiments were carried out in triplicate, and data are shown as means ± standard errors of the means (SEMs).
Results and Discussion
TEM images (Fig. 1) revealed that GS and Apt-GS were dispersed spherical structures with average diameters of 170-190 nm. The amount of conjugated aptamer on GS was approximately 0.65 μmol/g, as quantified using fluorescence spectra. FAM-labelled aptamer AS1411 was used for the synthesis to confirm coupling of the Apt peptide onto GS NPs. The intense green fluorescence (Fig.  1B, insert) suggested the presence of an aptamer in the sample.
Successfully RNAi can only occur when siRNA is delivered and released rapidly from its carrier into the cytoplasm. In this study, siRNA was conjugated to active Apt-GS NPs through the disulphide crosslinking reaction. To mimic intracellular conditions, the Apt-GS/siRNA NP complexes were reduced using 50 mM DTT for 2 h. siRNA molecules were observed in the polyacrylamide gel after treatment with DTT (Fig. 1C) , indicating that Apt-GS/siRNA NPs could reversibly release functional siRNA molecules by disulphide cleavage in the presence of a reducing reagent, such as glutathione in the cytosol. Additionally, the amount of siRNA on the nanoparticles was analysed by comparing the total amount of siRNA and control siRNA in 2% polyacrylamide gel electrophoresis. The Apt-GS encapsulated siRNA molecules at a weight ratio of 3:1-2:1 pmol/μg.
To assess the targeting efficiency of Apt-GS in tumour cells in vitro, we incubated A549 cells and 3T3 fibroblasts with the same amounts of FAM-labelled Apt-GS or control TDO-GS. Low levels of fluorescence could be observed in 3T3 cells or when cells were treated with control TDO-GS (GS decorated with a control oligonucleotide) (Fig. 1D) . In contrast, green fluorescence emitted by aptamer AS1411 was markedly enhanced in A549 cancer cells, suggesting that Apt-GS was specifically accumulated in tumour cells due to introduction of the nucleolin-targeted AS1411 aptamers. In the quantitative analysis by flow cytometry ( Fig. 2A-D) , the fluorescence intensities of internalized Apt-GS in A549 and 3T3 cells were enhanced 13 and 2 times from 0.5 to 16 h, respectively. Apt-GS NPs exhibited time-dependent fluorescence intensities in both cell types. Additionally, for cells treated with NPs, 96% of A549 cells were attached to or had taken up the NPs within 16 h, with the most dramatic increase observed in the first 30 min and an apparent maximum saturation at 8 h. In contrast, only 52% of 3T3 cells contained or were attached to NPs. To evaluate the role of nucleolin in the cellular uptake of NPs, the mixture of the prepared Apt-GS NPs and free AS1411 aptamers of varied concentrations (0.5, 5, and 50 μM) was incubated with A549 cells for 8 h. The fluorescence intensity and percentages of cells containing NPs decreased by 50% and 30%, respectively, when using the free AS1411 aptamer to compete with the Apt-GS NPs for nucleolin expressed at the cell membrane ( Fig. 2E and F) . These data suggested that nucleolin mediated the transmembrane process and demonstrated that Apt-GS NPs exhibited higher accumulation in A549 cancer cells via nucleolin-mediated internalization.
The gene knockdown (KD) efficiency of siRNA was assessed through luciferase activity after 48 h. Apt-GS/siRNA improved gene KD efficiency by 6-fold in A549 cells (Fig. 3A) . In contrast, the KD efficiency was only 6% in 3T3 fibroblasts, demonstrating tumour cell selectivity. Moreover, the subsequent addition of liposomes did not help to improve siRNA-mediated gene silencing, inferring siRNA release in the glutathione (GSH)-containing intracellular environment by disulphide cleavage. Additionally, when using a combination of liposomes and Apt-GS, transfection efficiency was improved to more than 40% though liposome-aided lysosome escape; however, cell selectivity was decreased. Notably, when using Lipofectamine 2000, a commercial transfection reagent, approximately 40% of luciferase expression was blocked in both cell types, which was higher than that of Apt-GS/siRNA conjugation but was also evidence of reduced cell selectivity.
Finally, we examined the effects of nanoparticle concentration on the RNAi efficiency. Gene interference efficiency reached the maximum at a complex concentration of 80 μg/ml (Fig. 3B) . Apt-GS can successfully deliver siRNA to tumour cells and subsequently permit specific RNAi-mediated knockdown of gene expression.
Conclusions
We developed an aptamer-and siRNA-conjugated gelatin-based nanoparticle for delivery of tumour-targeted siRNA. These Apt-GS/siRNA NPs could protect the cargo and demonstrated favourable release of siRNA under reducing conditions in response to disulphide cleavage.
Moreover, the Apt-GS/siRNA NPs could selectively target the siRNA to nucleolin-overexpressing A549 cells via nucleolin-mediated internalization, facilitating efficient RNAi. Thus, the Apt-GS/siRNA may have several potential applications in nucleolin-targeted RNAi in the future.
